Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | MIA-PaCa-2; MIA-PACA-2; MIA-Pa-Ca-2; MIA Paca2; MIA PaCa2; MiaPaCa-2; MIAPACA-2; MiaPaca.2; MiaPaCa2; Miapaca2; MIAPaCa2; MIAPACA2; Mia PACA 2; MIAPaCa-2; PaCa2; MiaPaCa |
| Species | Human |
| Cat.No | ABC-TC5587 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Pancreatic Ductal Adenocarinoma |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
MIA PaCa-2 is a human pancreatic tumor cell line originally derived from the pancreas of a 65-year-old Caucasian male patient with pancreatic ductal adenocarcinoma (PDAC). The cells exhibit epithelial-like morphology and semi-adherent growth characteristics, typically forming loosely attached clusters. The karyotype of MIA PaCa-2 shows hypotriploid, with a 61 of model chromosome number (PMID: 832918). MIA PaCa-2 contain abundant cytoplasm and are known to be sensitive to L-asparaginase treatment. As a tumorigenic cell line, MIA PaCa-2 readily forms tumors when subcutaneously implanted into immunodeficient (nude) mice, making it suitable for in vivo cancer studies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
MIA PaCa-2, is a widely used model for pancreatic cancer research, serves as a crucial tool in elucidating the biology of pancreatic ductal adenocarcinoma,particularly in studies of tumor progression, metastatic potential, and resistance to chemoradiotherapy. Additionally, MIA PaCa-2 is frequently used to analyze the morphological features of PDAC cells and to understand the cellular and molecular changes involved in pancreatic cancer development. This valuable information not only enhances our understanding of pancreatic ductal adenocarcinoma (PDAC) but also paves the way for the discovery of novel diagnostic biomarkers development of targeted therapies, contributing to more personalized and effective treatment strategies for pancreatic cancer patients.
